Alkemy Capital Investments Plc (LSE:ALK) rose 9.31% to 270.00p in the early-November 2026 session, a firm move for the lithium-processing developer on light turnover of around 11,790 shares (LSE:ALK). Listed on the London Stock Exchange's Main Market, where it was admitted in March 2022, the company is valued at roughly £27.77 million. With its Tees Valley Lithium project advancing, the question for investors is whether the gain reflects commercial progress or simply thin trading after a weak year.

Latest Developments

Alkemy Capital, through its Tees Valley Lithium (TVL) subsidiary, is developing lithium-hydroxide and wider battery-chemicals processing capacity in the north-east of England. (LSE:ALK) Its recent flow has been project-led, including a binding offtake agreement with Glencore, front-end engineering design (FEED) study updates, the appointment of Wates Group, the publication of an impact report, TVL project-development and industry-engagement updates, and a Loan conversion. These milestones point to a company moving its processing plans towards delivery.

What the Numbers Show

At 270.00p, Alkemy carries a Market Capitalisation of about £27.77 million. (LSE:ALK) Despite the project newsflow, the shares are down 24.61% over the trailing twelve months, so the latest session recovers part of that decline. The company is development-stage and loss-making, with a reported loss per share of £0.25 and no applicable price-to-earnings ratio, and it pays no dividend, leaving the Yield at 0%. A reported Beta of 0.19 is low, though for a thinly traded development stock such a figure should be read as indicative only. No third-party data-provider rating is attached.

Why Investors Are Watching

Alkemy sits in a strategically significant niche: domestic processing of lithium chemicals for the UK and European battery Supply chain, a priority as manufacturers seek to reduce reliance on imported material. A binding offtake agreement with a major commodities group such as Glencore is a meaningful validation signal, giving a potential route to market for future output. For a Main Market small-cap, converting engineering studies and offtake arrangements into funded construction is the key progression investors track.

What Could Come Next

The forward agenda is likely to feature completion of engineering work, a final investment decision, project financing, and further offtake or Partnership announcements. Any clarity on capital funding and timelines to production would be the catalysts most capable of re-rating the shares. Given the scale of capital required for processing facilities, financing news will be watched as closely as technical and permitting progress.

Risks to Watch

The central risks are funding and execution: building processing capacity is capital-intensive, and the loss-making company will likely need substantial financing, raising dilution risk. Project timelines can slip, and lithium-chemical Economics are sensitive to volatile Commodity prices. Liquidity is limited, as the light session Volume shows, and while the stock trades on the Main Market it sits outside the FTSE 350 at the higher-risk end of the market.

Conclusion

Alkemy Capital Investments' 9.31% gain in the early-November 2026 session recovers some ground after a weak twelve months, supported by tangible progress at Tees Valley Lithium, including the Glencore offtake. With financing and construction decisions still ahead, the figures capture both the strategic appeal of domestic lithium processing and the execution risks facing this development-stage Main Market small-cap.